Looking to take on an exciting new career as a travel nurse or pick up a new contract in a new city or state? Millenia Medical Staffing offers travel nursing assignments across the US from California to Texas to Florida and New York, we can help place you with at a top facility with a high paying contract. To get started, simply visit us online or call one of our recruiters today at 888-686-6877.
One of the exciting perks of being a travel nurse is getting to go somewhere new, experience a new city, and see if its a right fit for you. When you partner with Millenia Medical for your travel nursing assignment, you can expect great pay, benefits, and housing, so it is easy to pick up and head to the beach down in Florida or north like New York or Maine. Travel nursing is a great option for nurses that have flexibility to leave their home city. Our contacts range from four weeks to twenty six weeks, so you can find a contract length that meets your needs.
We pride ourselves on offering exceptional benefits to qualified travel nurses that we place at top medical facilities, and we have done so since 1999. We can help you find a contract that matches your skills and offer you great benefits. When you want to apply for travel nursing positions, go online or give our recruiters a call, we can help you find the right position.
Millenia Medical Staffing has travel nursing contracts with some of the best medical facilities around the US. Whether you are looking to start a new career, experience a new town, or simply want a change of scenery, Millenia Medical makes it possible. There is such a large inventory of available contracts that you can be sure to find exactly what you are looking for, give us a call today at 888-686-6877.
Millenia Medical Offers Top Paying Travel Nursing Contracts To Travel Nurses
In celebration of International Nurses Week, Millenia Medical invites existing travel nurses and nurses looking into the travel nursing sector to apply for 13 week travel nursing assignments online. We recognize how valuable you are to our society and how much hard work and energy you put into your job each and everyday. With International Nurses Week, the time to say Thank You is now, and everyday, for devoting your lives to help others.
We take great pride in offering our travel nurses with exceptional benefits and pay. Knowing and recognizing your efforts in the healthcare industry means you can expect top pay rates in the travel nursing healthcare industry from Millenia Medical. We also provide competitive insurance packages, travel reimbursement, deluxe private housing and more. When you are looking to get into the travel nursing industry, it is important to consider all aspects of your contract, so give us a call to see what all we can offer you.
We are proud to announce that since 1999, we have placed travel nurses with exceptional contractors. Thanks to our connections with top medical facilities nationwide, which includes government facilities, critical access to major teaching hospitals, as well as Indian Health Services, you can go exciting and rewarding places as a travel nurse with us.
With International Nurses Week in full swing, we can’t say thank you enough to our nurses and nurses worldwide. 2020 brought new challenges to the healthcare industry and we see and recognize how hard you all have worked. We appreciate all that you do and recognize that nursing is often a thankless job.
Inquire with Millenia Medical today about highest paying 13 week travel nursing assignments and start your new contract with us, call 888-686-6877 for more information.
Global WholeHealth Partners Corp (OTC: GWHP) to Announce that Global is Now Offering the AstraZeneca Vaccines for $17.50 Per Vaccine as Mentioned in 8k Filing 03/08/21
Global WholeHealth Partners Corp (OTC: GWHP) continues the fight against COVID 19 by now offering the Vaccine for just $17.50 per vaccine.
Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster.
VOLUME 397, ISSUE 10277, P854-855, MARCH 06, 2021
Call (949) 757-4152 to place your order and get an allocation or email Global at Sales@gwhpcorp.com
“Global understands that this is a war on COVID 19 and we are expanding our line of products to be able to fight,” states CEO Charles Storngo.
“This is a wartime undertaking,” Biden said. “Today, I’m signing executive action to use the Defense Production Act and all other available authorities to direct all federal agencies and private entities to accelerate the making of everything that’s needed to protect, test, vaccinate, and take care of our people.”
Under Mr. Strongo’s direction, Global is following the President and his leadership and is making a war on COVID. To conquer COVID and win this war, Global must keep up the research and development of tests. We are continuing to offer more tests and now vaccines to win this war on COVID 19.
Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest line of COVID 19 tests. Global’s WholeHealth Partners Corp (OTC: GWHP) states that the Antibody IgG/IgM tests that they offer is capable of detecting all the current identified SARS-CoV-2 viruses. The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) strain contains multiple mutations, most reflected in the S gene, which encodes the spike protein, Global understands the need to be ahead of the virus to conquer the virus. Now, with the vaccine, Global is offering one of the largest lines of products to fight this virus.
Mr. Strongo states, “Antibody and Antigen Testing is critical to fight against CoViD 19 SARS 2.”
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.
As a third surge of the coronavirus threatens much of the United States, public health experts across the country say there still aren’t enough tests available to keep the virus under control.
About 30 million Covid-19 tests are given every month, according to estimates from The Atlantic magazine’s Covid Tracking Project. But studies have found that the U.S. would need millions more —193 million a month, according to one report — to be effective.
The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test
Global Wholehealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013, and is headquartered in San Clemente, CA.
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, GWHP offers a CE Mark for its high quality, rapid antibody test for COVID-19 and an EUA filing with the FDA is pending approval. In the interim, the US Navy in California has been using the test during 2Q20 and the Company has the capacity to deliver hundreds of thousands of tests, ramping up to 1 million per day. Currently, the Company offers 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or revise its forward-looking statements as a result of new information, future events or otherwise.
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the execution of a Letter of Intent with Silo Pharma Inc. (“Silo”) to grant to AIkido a worldwide, exclusive sublicense for use of peptide therapy, combined with psilocybin, in the therapeutic treatment of neuroinflammatory disease in cancer patients. This Letter of Intent is in addition to the January 6, 2021, licensing agreement between AIkido Pharma and Silo and these additional assets expand the Company’s asset base in the area of psilocybin to treat cancer.
The Company notes that there is no assurance that the proposal will result in a binding agreement with Silo or that the transaction contemplated by the Letter of Intent, or any other transaction between the parties, will be completed. The transaction is subject to customary due diligence. Consummation of the transaction is necessarily further subject to entering into a definitive agreement between the parties containing specific signing and closing terms and conditions yet to be negotiated.
This press release shall not constitute an offer to sell or the solicitation of an offer to acquire any securities, nor shall there be any sale of any securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.